Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 839706-07-9 Chemical Structure| 839706-07-9

Structure of GNF-7
CAS No.: 839706-07-9

Chemical Structure| 839706-07-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

GNF-7 inhibits Bcr-Abl WT and Bcr-Abl T315I with IC50 of 133 nM and 61 nM, respectively.

Synonyms: GNF-7

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of GNF-7

CAS No. :839706-07-9
Formula : C28H24F3N7O2
M.W : 547.53
SMILES Code : O=C(NC1=CC=C(C)C(N2CC3=CN=C(NC4=CC=C(C)N=C4)N=C3N(C)C2=O)=C1)C5=CC=CC(C(F)(F)F)=C5
Synonyms :
GNF-7
MDL No. :MFCD18251569
InChI Key :SZNYUUZOQHNEKB-UHFFFAOYSA-N
Pubchem ID :11478363

Safety of GNF-7

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H301
Precautionary Statements:P301+P310
Class:6.1
UN#:2811
Packing Group:

Related Pathways of GNF-7

RTK

Isoform Comparison

Biological Activity

Target
  • Abl

    E255V, IC50:122 nM

    M351T, IC50:133 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
Hela cells 50 μM 2 days GNF-7 treatment reduced miR-21-5p levels to ~35% compared to the controls. PMC10066322
Ba/F3-T315I-Bcr-Abl 11 nM To evaluate the antiproliferative activity of GNF-7 against T315I Bcr-Abl mutant cells PMC4134510
OCI-AML3 (NRAS-Q61L) 0.229 ± 0.010 µM (GI50 ) 72 hours Evaluate anti-proliferative activity, results showed GNF-7 inhibited NRAS-Q61L mutated OCI-AML3 cells PMC8695447
HT-29 (KRAS-Q61L) 0.938 ± 0.034 µM (GI50 ) 72 hours Evaluate anti-proliferative activity, results showed GNF-7 inhibited KRAS-Q61L mutated HT-29 cells PMC8695447
MDA-MB-231 (KRAS-G13D) 0.296 ± 0.039 µM (GI50 ) 72 hours Evaluate anti-proliferative activity, results showed GNF-7 inhibited KRAS-G13D mutated MDA-MB-231 cells PMC8695447
SW480 (KRAS-G12V) 0.760 ± 0.063 µM (GI50 ) 72 hours Evaluate anti-proliferative activity, results showed GNF-7 inhibited KRAS-G12V mutated SW480 cells PMC8695447
DU-145 (KRAS-G12V) 0.288 ± 0.057 µM (GI50 ) 72 hours Evaluate anti-proliferative activity, results showed GNF-7 inhibited KRAS-G12V mutated DU-145 cells PMC8695447
AsPC-1 (KRAS-G12D) 0.448 ± 0.027 µM (GI50 ) 72 hours Evaluate anti-proliferative activity, results showed GNF-7 inhibited KRAS-G12D mutated AsPC-1 cells PMC8695447
H358 (KRAS-G12C) 0.922 ± 0.093 µM (GI50 ) 72 hours Evaluate anti-proliferative activity, results showed GNF-7 inhibited KRAS-G12C mutated H358 cells PMC8695447
Ba/F3 cells (NRAS-G12V transformed) 0.396 ± 0.036 µM (GI50 ) 72 hours Evaluate anti-proliferative activity, results showed GNF-7 inhibited NRAS-G12V transformed Ba/F3 cells PMC8695447
Ba/F3 cells (NRAS-G12D transformed) 0.250 ± 0.026 (GI50 ) 72 hours Evaluate anti-proliferative activity, results showed GNF-7 inhibited NRAS-G12D transformed Ba/F3 cells PMC8695447
WM3629 0.21 ± 0.00 μM (GI50 ) 72 hours Evaluate anti-proliferative activity, GNF-7 showed anti-proliferative activity on WM3629 cells PMC8038755
WM3670 0.13 ± 0.01 μM (GI50 ) 72 hours Evaluate anti-proliferative activity, GNF-7 showed anti-proliferative activity on WM3670 cells PMC8038755
C8161 0.02 ± 0.00 μM (GI50 ) 72 hours Evaluate anti-proliferative activity, GNF-7 showed anti-proliferative activity on C8161 cells PMC8038755
A375 0.06 ± 0.00 μM (GI50 ) 72 hours Evaluate anti-proliferative activity, GNF-7 showed anti-proliferative activity on A375 cells PMC8038755
SK-MEL-28 0.15 ± 0.02 μM (GI50 ) 72 hours Evaluate anti-proliferative activity, GNF-7 showed anti-proliferative activity on SK-MEL-28 cells PMC8038755
HEK293T >10 uM To evaluate the growth inhibitory activity of GNF-7 against non-cancer cells PMC4134510
SW620 0.001 uM To evaluate the growth inhibitory activity of GNF-7 against colon cancer cells PMC4134510
Colo205 0.005 uM To evaluate the growth inhibitory activity of GNF-7 against colon cancer cells PMC4134510
SK-MEL-2 0.23 ± 0.08 μM (GI50 ) 72 hours Evaluate anti-proliferative activity, GNF-7 showed anti-proliferative activity on SK-MEL-2 cells PMC8038755

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice BaLb/C Mice Oral 10 mg/kg or 20 mg/kg Once daily To evaluate the inhibitory effect of GNF-7 on T315I-Bcr-Abl-dependent tumor growth PMC4134510
C57BL/6 mice DSS-induced colitis model Intraperitoneal injection 5 mg/kg Once daily for 7 days To evaluate the therapeutic potential of 7a in DSS-induced colitis model. 7a treatment significantly improved clinical symptoms, including disease activity index (DAI) scores and recovery of colon length shortening. PMC9067983

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.83mL

0.37mL

0.18mL

9.13mL

1.83mL

0.91mL

18.26mL

3.65mL

1.83mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories